Results 151 to 160 of about 4,421,151 (391)

A comparison of smokers' and ex-smokers' health-related quality of life [PDF]

, 1997
Maria Tillmann, Jonathan Silcock
openalex   +1 more source

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Health-related quality of life impairment is equal for antiphospholipid syndrome whether primary or associated with systemic lupus erythematosus

Rheumatology
Introduction Antiphospholipid syndrome (APS) manifests with thrombosis and pregnancy losses and may significantly impair the health-related quality of life (HRQoL).
Ewa Haladyj, Agata Matusiewicz, Tomasz Wysocki, Marzena Olesinska   +3 more
doaj   +1 more source

Health-related quality of life after liver transplantation [PDF]

, 1998
Anna Hellgren, B. Berglund, Ulriqa Gunnarsson, Karin Hansson, Ulla Norberg, Lars Bäckman   +5 more
openalex   +1 more source

Health-Related Quality of Life [PDF]

Cephalalgia, 1995
openaire   +2 more sources

Health-related quality of life in the WA HIV Cohort: 2008 [PDF]

, 2009
Quality of life (QOL) is an important outcome of HIV treatment and a priority in the management of HIV. A new Patient-Reported Outcomes (PRO) questionnaire to measure the QOL in people living with HIV/AIDS (PLWHA) from different cultures and language ...
Acquadro, C., Duracinsky, M., Herrmann, S., Lalanne, C., Mallal, S., Nolan, D.   +5 more
core   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Assessment of health status and health-related quality of life in survivors of Hodgkin's disease in childhood [PDF]

, 1999
Charmaine S. Van Schaik, Ronald D. Barr, Sonja Depauw, William Furlong, David Feeny   +4 more
openalex   +1 more source

Hubungan Antara Adversity Intelligence Dengan Health-related Quality of Life Pada Mahasiswa S1 Angkatan 2010 Fakultas Kedokteran Universitas Diponegoro Semarang [PDF]

, 2012
This research aimed to find out whether variables Adversity Intelligence having correlation with variable Health-related Quality of Life. Population in this research is student class 2010 of Medicine Faculty, Diponegoro University and using proportional ...
Choirunnisa, E. (Erysa), Hidayati, F. (Farida), Prihatsanti, U. (Unika)   +2 more
core  

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source